Successful Desensitization with Crizotinib after Crizotinib-induced Liver Injury in ROS1-rearranged Lung Adenocarcinoma

Crizotinib has been approved for patients with advanced lung adenocarcinoma harboring rearrangements of the c-ROS-1 (ROS1) and anaplastic lymphoma kinase (ALK) genes. We report a patient with ROS1-rearranged lung adenocarcinoma who developed a crizotinib-induced mixed/cholestatic type of liver injur...

Descripción completa

Detalles Bibliográficos
Autores principales: Ota, Takayo, Masuda, Noriyuki, Matsui, Kaoru, Yamada, Takao, Tanaka, Noriko, Fujimoto, Shunsuke, Fukuoka, Masahiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Japanese Society of Internal Medicine 2019
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6794186/
https://www.ncbi.nlm.nih.gov/pubmed/31178493
http://dx.doi.org/10.2169/internalmedicine.2554-18
_version_ 1783459240936996864
author Ota, Takayo
Masuda, Noriyuki
Matsui, Kaoru
Yamada, Takao
Tanaka, Noriko
Fujimoto, Shunsuke
Fukuoka, Masahiro
author_facet Ota, Takayo
Masuda, Noriyuki
Matsui, Kaoru
Yamada, Takao
Tanaka, Noriko
Fujimoto, Shunsuke
Fukuoka, Masahiro
author_sort Ota, Takayo
collection PubMed
description Crizotinib has been approved for patients with advanced lung adenocarcinoma harboring rearrangements of the c-ROS-1 (ROS1) and anaplastic lymphoma kinase (ALK) genes. We report a patient with ROS1-rearranged lung adenocarcinoma who developed a crizotinib-induced mixed/cholestatic type of liver injury. The patient discontinued crizotinib after 34 days due to liver toxicity. Twenty-four days later, when transaminases and C reactive protein (CRP) were normalized, crizotinib was resumed using an oral desensitization method. The patient was successfully treated for manageable recurrence of liver injury and has been able to continue the treatment.
format Online
Article
Text
id pubmed-6794186
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher The Japanese Society of Internal Medicine
record_format MEDLINE/PubMed
spelling pubmed-67941862019-10-17 Successful Desensitization with Crizotinib after Crizotinib-induced Liver Injury in ROS1-rearranged Lung Adenocarcinoma Ota, Takayo Masuda, Noriyuki Matsui, Kaoru Yamada, Takao Tanaka, Noriko Fujimoto, Shunsuke Fukuoka, Masahiro Intern Med Case Report Crizotinib has been approved for patients with advanced lung adenocarcinoma harboring rearrangements of the c-ROS-1 (ROS1) and anaplastic lymphoma kinase (ALK) genes. We report a patient with ROS1-rearranged lung adenocarcinoma who developed a crizotinib-induced mixed/cholestatic type of liver injury. The patient discontinued crizotinib after 34 days due to liver toxicity. Twenty-four days later, when transaminases and C reactive protein (CRP) were normalized, crizotinib was resumed using an oral desensitization method. The patient was successfully treated for manageable recurrence of liver injury and has been able to continue the treatment. The Japanese Society of Internal Medicine 2019-06-07 2019-09-15 /pmc/articles/PMC6794186/ /pubmed/31178493 http://dx.doi.org/10.2169/internalmedicine.2554-18 Text en Copyright © 2019 by The Japanese Society of Internal Medicine https://creativecommons.org/licenses/by-nc-nd/4.0/ The Internal Medicine is an Open Access journal distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. To view the details of this license, please visit (https://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Case Report
Ota, Takayo
Masuda, Noriyuki
Matsui, Kaoru
Yamada, Takao
Tanaka, Noriko
Fujimoto, Shunsuke
Fukuoka, Masahiro
Successful Desensitization with Crizotinib after Crizotinib-induced Liver Injury in ROS1-rearranged Lung Adenocarcinoma
title Successful Desensitization with Crizotinib after Crizotinib-induced Liver Injury in ROS1-rearranged Lung Adenocarcinoma
title_full Successful Desensitization with Crizotinib after Crizotinib-induced Liver Injury in ROS1-rearranged Lung Adenocarcinoma
title_fullStr Successful Desensitization with Crizotinib after Crizotinib-induced Liver Injury in ROS1-rearranged Lung Adenocarcinoma
title_full_unstemmed Successful Desensitization with Crizotinib after Crizotinib-induced Liver Injury in ROS1-rearranged Lung Adenocarcinoma
title_short Successful Desensitization with Crizotinib after Crizotinib-induced Liver Injury in ROS1-rearranged Lung Adenocarcinoma
title_sort successful desensitization with crizotinib after crizotinib-induced liver injury in ros1-rearranged lung adenocarcinoma
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6794186/
https://www.ncbi.nlm.nih.gov/pubmed/31178493
http://dx.doi.org/10.2169/internalmedicine.2554-18
work_keys_str_mv AT otatakayo successfuldesensitizationwithcrizotinibaftercrizotinibinducedliverinjuryinros1rearrangedlungadenocarcinoma
AT masudanoriyuki successfuldesensitizationwithcrizotinibaftercrizotinibinducedliverinjuryinros1rearrangedlungadenocarcinoma
AT matsuikaoru successfuldesensitizationwithcrizotinibaftercrizotinibinducedliverinjuryinros1rearrangedlungadenocarcinoma
AT yamadatakao successfuldesensitizationwithcrizotinibaftercrizotinibinducedliverinjuryinros1rearrangedlungadenocarcinoma
AT tanakanoriko successfuldesensitizationwithcrizotinibaftercrizotinibinducedliverinjuryinros1rearrangedlungadenocarcinoma
AT fujimotoshunsuke successfuldesensitizationwithcrizotinibaftercrizotinibinducedliverinjuryinros1rearrangedlungadenocarcinoma
AT fukuokamasahiro successfuldesensitizationwithcrizotinibaftercrizotinibinducedliverinjuryinros1rearrangedlungadenocarcinoma

Ejemplares similares